![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AbbVie-Allergan Merger Gets Final Clearance in Europe
AbbVie-Allergan Merger Gets Final Clearance in Europe
![Allergan and AbbVie](https://www.fdanews.com/ext/resources/test/Drug-Images4/abbvie-Allergan-logo.gif?t=1583963435&width=430)
March 11, 2020
The European Commission has approved the divestiture of Allergan’s brazikumab to AstraZeneca, paving the way for Allergan’s $63 billion acquisition by AbbVie.
The commission required Allergan to sell off its investigational drug, an IL-23 inhibitor candidate for Crohn’s disease and ulcerative colitis, because the merger could disrupt development of the innovative treatment.
The two companies said they are expecting a decision on the merger by the Federal Trade Commission early in the second quarter of 2020.
Upcoming Events
-
21Oct